JCRB1082 KYSE170
細胞情報
Important Notice(s)On the MTA of KYSE series cell lines with Kyoto University (for profit organizations)
Announcement of unavailability of KYSE series cell lines to oversea users outside of Japan
細胞種類:一般細胞 (細胞分譲手数料はこちら)
細胞番号(JCRB) | JCRB1082 | 細胞名 | KYSE170 |
---|---|---|---|
生物種(日本語) | ヒト | 組織名(日本語) | 食道 |
コメント(日本語) | 扁平上皮がん, 中分化型, (民間企業利用者は、分譲依頼前に細胞樹立者とMTAを手交する必要があります。) | プロフィール | Human squamous cell carcinoma cell line established from esophageal cancer. |
別名 | 動物名 | human | |
系統名 | 学名・属名 | Homo | |
種名 | sapiens | 性別 | F |
年齢・月齢 | 53 | 細胞識別情報 | available |
(癌)原発組織名 | esophagus | 病歴情報 | esophagus cancer, T3N0M0 Stage 2a, squamous cell carcinoma (SCC) |
転移の有無(Y/N) | No | (癌)転移組織名 | |
遺伝的性質 | C-Myc and MDM2 amplification observed. p53 mutation, FHIT. | 細胞寿命 | infinite |
クライシスPDL | 形態 | epithelial-like | |
一般性状 | Xenotransplantation positive. | 細胞分類 | tumor |
細胞樹立者名 | Shimada,Y. | 細胞寄託者 | Shimada,Y. |
分譲時制限 | Cite reference {5368}. Company users require MTA from the originator. Japan domestic use only. | コメント | Distribution restricted to Japan(domestic use only). |
入手年 | 2003 | 培養培地 | Ham's F12 medium + RPMI1640 medium (1 to 1 mix) with 2% fetal calf serum. |
継代方法 | Cells harvested after treatment with trypsin and EDTA. | 継代時細胞数 | split ratio = 1/5 |
人種 | Japanese | 炭酸ガス濃度 | 5 % |
採取組織名 | esophagus | 組織型 | mederately differenciated SCC |
ウイルスDNA・RNA検出検査 (Detection of virus genome fragment by Real-time PCR) | |||||||||
---|---|---|---|---|---|---|---|---|---|
ウイルスDNA 検出検査 |
tested | ウイルスRNA 検出検査 |
tested | ||||||
CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
BKV | - | HIV-1 | - | ||||||
JCV | - | HIV-2 | - | ||||||
ADV | - | HPV18 | - | ||||||
Notes |
Reference | |
---|---|
Pubmed id:11092977 | Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon. Pimkhaokham A,Shimada Y,Fukuda Y,Kurihara N,Imoto I,Yang ZQ,Imamura M,Nakamura Y,Amagasa T,Inazawa J Jpn J Cancer Res. 2000 Nov;91(11):1126-33 |
Pubmed id:10446988 | Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma. Harada H,Tanaka H,Shimada Y,Shinoda M,Imamura M,Ishizaki K Cancer Res. 1999 Aug 1;59(15):3724-9 |
Pubmed id:9699676 | Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Tanaka H,Shimada Y,Harada H,Shinoda M,Hatooka S,Imamura M,Ishizaki K Cancer Res. 1998 Aug 1;58(15):3429-34 |
Pubmed id:9033652 | Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Tanaka H,Shimada Y,Imamura M,Shibagaki I,Ishizaki K Int J Cancer. 1997 Feb 7;70(4):437-42 |
Pubmed id:8575860 | Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Tanaka H,Shibagaki I,Shimada Y,Wagata T,Imamura M,Ishizaki K Int J Cancer. 1996 Jan 26;65(3):372-6 |
Pubmed id:9816044 | p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Shibagaki I,Tanaka H,Shimada Y,Wagata T,Ikenaga M,Imamura M,Ishizaki K Clin Cancer Res. 1995 Jul;1(7):769-73 |
Pubmed id:7913084 | Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Kanda Y,Nishiyama Y,Shimada Y,Imamura M,Nomura H,Hiai H,Fukumoto M Int J Cancer. 1994 Jul 15;58(2):291-7 |
Pubmed id:8518899 | Prognostic significance of cell culture in carcinoma of the oesophagus. Shimada Y,Imamura M Br J Surg. 1993 May;80(5):605-7 |
Pubmed id:1728357 | Characterization of 21 newly established esophageal cancer cell lines. Shimada Y,Imamura M,Wagata T,Yamaguchi N,Tobe T Cancer. 1992 Jan 15;69(2):277-84 |
Images |
---|
LOT Information
細胞番号 | JCRB1082 | 細胞名 | KYSE170 |
---|---|---|---|
培養ロット番号 | 10272004 | 培養種別 | distribution |
培地 | RPMI1640 and Ham's F12 medium(1/1) with 2% heat inactivated fetal bovine serum | 培養温度 | 37 C |
継代時細胞数(濃度) | 4.5x10^4 | 継代方法 | 0.25% trypsin and 0.02% EDTA |
増殖速度 | NT | 凍結時生細胞濃度 | 2.7x10^6 |
凍結時生細胞率 | 93.2 | 使用抗生物質 | Free |
継代数 | P691 | PDL数(プライマリ) | NT |
マイコプラズマ検出 | - | 細菌汚染検出 | NT |
真菌汚染検出 | NT | アイソザイム検査・動物名 | NT |
染色体モード | NT | 染色体情報 | NT |
表面抗原 | NT | DNA Profile (STR) | |
接着性 | Yes | 導入外部遺伝子 | NT |
凍結培地 | Culture medium with final 10% fetal bovine serum and 5% DMSO | 炭酸ガス濃度 | 5 % |
解凍後生細胞率 | 追加情報 |
Images |
---|
細胞番号 | JCRB1082 | 細胞名 | KYSE170 |
---|---|---|---|
培養ロット番号 | 10052015 | 培養種別 | distribution |
培地 | 1:1 mixture of Ham's F12 medium and RPMI1640 medium with 2% heat-inactivated fetal bovine serum (FBS; GIBCO Cat. # 10091). | 培養温度 | 37 C |
継代時細胞数(濃度) | 5.8 - 9.8 x 10^5 cells/mL | 継代方法 | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
増殖速度 | 19 - 29 hrs | 凍結時生細胞濃度 | 2.4 x 10^6 |
凍結時生細胞率 | 96.8 | 使用抗生物質 | free |
継代数 | P690 | PDL数(プライマリ) | |
マイコプラズマ検出 | - | 細菌汚染検出 | - |
真菌汚染検出 | - | アイソザイム検査・動物名 | |
染色体モード | 染色体情報 | ||
表面抗原 | DNA Profile (STR) | D5S818:11,12,13 D13S317:9 D7S820:11,12 D16S539:9,10 VWA:16,17 TH01:7,9 AM:X TPOX:11 CSF1PO:10,12,13 |
|
接着性 | Yes | 導入外部遺伝子 | |
凍結培地 | 10% DMSO, 20% FBS - culture medium | 炭酸ガス濃度 | 5% |
解凍後生細胞率 | 96.8 | 追加情報 |